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Introduction
Oncogenic  proliferative  signals  are  coupled  to  a  variety  of 
growth inhibitory processes (Lowe et al., 2004; Campisi, 2005; 
Sharpless and DePinho, 2005). For example, in cultured pri-
mary human fibroblasts, ectopic expression of oncogenic Ras 
or its downstream mediator initiates cellular senescence, the 
state of irreversible cell cycle arrest, through up-regulation of 
Cdk inhibitors such as p16
Ink4a (Serrano et al., 1997; Lin et al., 
1998; Zhu et al., 1998; Ohtani et al., 2001). Some contribution 
to cellular senescence presumably underlies the importance of 
p16
Ink4a as a tumor suppressor, but the roles and mechanisms 
regulating its expression in vivo remain elusive (Michaloglou 
et al., 2005; Gil and Peters, 2006; Kim and Sharpless, 2006; 
Takahashi et al., 2006). To date, much of our current knowl-
edge of how human p16
Ink4a gene expression is induced by on-
cogenic stimuli derives from studies undertaken in cultured 
primary cells (Serrano and Blasco, 2001; Gil and Peters, 2006; 
Kim and Sharpless, 2006). However, because human p16
Ink4a 
gene  expression  is  also  induced  by  tissue  culture–imposed 
stress (Ramirez et al., 2001; Benanti and Galloway, 2004; Ince 
et al., 2007; Shay and Wright, 2007), it remains unclear whether 
the induction of human p16
Ink4a gene expression in tissue- 
cultured cells truly reflects an anticancer process or an artifact 
of tissue culture–imposed stress.
We believe that p16
Ink4a knockout mice are powerful tools 
to elucidate the physiological roles of p16
Ink4a gene expression 
in vivo. However, one limitation of this approach is the develop-
mental or somatic compensation by up-regulation of remaining 
p16
Ink4a family genes in p16
Ink4a knockout mice (Krimpenfort   
  E
xpression of the p16
Ink4a tumor suppressor gene, a 
sensor of oncogenic stress, is up-regulated by a va-
riety of potentially oncogenic stimuli in cultured pri-
mary cells. However, because p16
Ink4a expression is also 
induced by tissue culture stress, physiological mechanisms 
regulating p16
Ink4a expression remain unclear. To elimi-
nate any potential problems arising from tissue culture–
imposed  stress,  we  used  bioluminescence  imaging  for 
noninvasive and real-time analysis of p16
Ink4a expression 
under various physiological conditions in living mice. 
In this study, we show that oncogenic insults such as ras 
activation provoke epigenetic derepression of p16
Ink4a 
expression through reduction of DNMT1 (DNA methyl 
transferase 1) levels as a DNA damage response in vivo. 
This pathway is accelerated in the absence of p53, indi-
cating that p53 normally holds the p16
Ink4a response in 
check.  These  results  unveil  a  backup  tumor  suppressor 
role for p16
Ink4a in the event of p53 inactivation, expand-
ing our understanding of how p16
Ink4a expression is regu-
lated in vivo.
Real-time in vivo imaging of p16
Ink4a reveals cross 
talk with p53
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Figure 1.  Generation of human p16
Ink4a reporter mice. (A) A large genomic DNA segment (195.4 kb) of human chromosome that contains the entire 
INK4a/ARF gene locus and surrounding sequences, including a putative DNA replication origin (RD) known to regulate p16
Ink4a gene expression (Gonzalez 
et al., 2006), was engineered to express luciferase-tagged p16
Ink4a. (B) BAC vector containing p16-luc DNA or empty BAC vector was transfected into 
293T cells. Expression of the p16
Ink4a-luciferase fusion protein was analyzed by Western blotting after selection with antibiotics. (C) BAC vector containing 
p16-luc DNA was introduced into 293T cells with or without BMI-1 expression plasmid along with 0.2 mg of MMLV (Moloney murine leukaemia virus)-lacZ 
plasmid. Luciferase activities were normalized by lacZ activities. Error bars indicate SD. (D) The 6-wk-old p16-luc mice were subjected to noninvasive BLI. 
Representative images of five different experiments are shown (left). The same mice were incised through the mouth and anus under anesthesia. Representa-
tive BLI data of five different experiments are shown. The color bar indicates photons with minimum and maximum threshold values. (E) Bioluminescence 395 REAL-TIME IN VIVO IMAGING OF P16 EXPRESSION • Yamakoshi et al.
intensity emitted from the organs was graphed (log10 scale). The mean ± SD of five independent experiments is shown. (F) The levels of exogenous (human) 
p16
Ink4a gene expression and endogenous (mouse) p16
Ink4a gene expression in p16-luc mice were analyzed by semiquantitative RT-PCR. -Actin was used 
as a loading control. Representative data of five different experiments are shown.
 
et al., 2007; Ramsey et al., 2007; Wiedemeyer et al., 2008). 
Moreover, the possibility of cross-species differences between   
human p16
Ink4a expression and mouse p16
Ink4a expression also 
complicates the interpretation of p16
Ink4a knockout mouse data 
(Gil and Peters, 2006). Therefore, alternative approaches are 
also needed to supplement the tissue culture studies and to assist 
in understanding the roles and mechanisms regulating human 
p16
Ink4a gene expression in vivo.
In this study, we developed a new transgenic mouse model 
that carries the entire human p16
Ink4a gene locus tagged with 
firefly luciferase. In this mouse model, luciferase activity allows 
expression of the human p16
Ink4a gene to be monitored under 
various physiological conditions in the context of living ani-
mals. Interestingly, the human p16
Ink4a gene behaved in the same 
way as the mouse p16
Ink4a gene in living mice, indicating that 
this mouse model is an ideal tool for studying physiological re-
sponse of p16
Ink4a gene expression in vivo. Using this system, in 
conjunction with various tissue culture experiments, we show in 
this study that oncogenic Ras signaling provokes p16
Ink4a gene 
expression through a reduction of DNMT1 (DNA methyl trans-
ferase 1) levels as a DNA damage response (DDR) in vivo. 
Furthermore, this pathway is accelerated in the setting of p53 
deletion, indicating that there is a regulatory feedback circuit 
between the p53 and p16
Ink4a tumor suppressors. This un-
expected regulatory circuit is likely to elicit a backup tumor sup-
pressor role for p16
Ink4a after p53 inactivation, facilitating our 
understanding of how these critical tumor suppressor genes are 
networked in vivo.
Results
Visualization of human p16
Ink4a gene 
expression in living animals
To monitor human p16
Ink4a gene expression as accurately as 
possible, we used a large genomic DNA segment of the human 
chromosome that contains the entire Ink4a/Arf gene locus   
(Fig. 1 A). Furthermore, this chromosome segment was engi-
neered to express a fusion protein of human p16
Ink4a and firefly 
luciferase  (p16-luc)  without  deleting  any  genomic  DNA  se-
quences at the Ink4a/Arf gene locus (Fig. 1, A and B). This is 
very important because BMI-1, which is a negative regulator of 
p16
Ink4a gene expression (Jacobs et al., 1999), is known to bind 
not only to the promoter region but also to the intron region of 
the p16
Ink4a locus (Bracken et al., 2007; Kotake et al., 2007). 
Moreover, the expression of p16-luc fusion protein enables us 
to specify p16
Ink4a gene expression but not Arf gene expression 
from this overlapping gene locus. It is noteworthy that over-
expression of p16-luc did not have any significant impact on phos-
phorylation of retinoblastoma tumor suppressor protein (pRb), 
although similar levels of p16
Ink4a expression efficiently blocked 
pRb phosphorylation in U2OS cells, suggesting that p16-luc 
does not function as a Cdk inhibitor (Fig. S1 A). However,   
importantly, a significant level of luciferase activity was observed 
and was reduced when this recombinant human chromosome 
segment (p16-luc DNA) was cointroduced with a BMI-1 expres-
sion vector into tissue culture cells (Fig. 1 C). Together, these 
results indicate that p16-luc DNA would be an ideal tool to moni-
tor human p16
Ink4a gene expression in vivo, especially in the 
context of living animals.
Therefore,  a  transgenic  mouse  line  that  carries  p16-luc 
DNA (p16-luc mouse) was established that had incorporated the 
entire p16-luc DNA segment into its genome as judged by FISH, 
Southern blotting, and PCR analysis (Fig. S1 B and not depicted). 
To examine the copy number of the transgene, genomic DNA 
was prepared from early passage mouse embryonic fibroblasts 
(MEFs) derived from the p16-luc mice. The DNA sequence spe-
cific to this human chromosome segment was amplified and 
quantified  by  real-time  PCR  analysis  (Ballester  et  al.,  2004; 
Chandler et al., 2007) using genomic DNA prepared from the 
same number of early passage human diploid fibroblasts (HDFs) 
as a control. The signals obtained from the p16-luc MEFs were 
almost half compared with those from HDFs, which have two 
copies of the human Ink4a/Arf gene (Fig. S1 C). These results, 
together with the FISH analysis data (Fig. S1 B), suggest that the 
p16-luc mouse strain contains a single copy of the p16-luc DNA 
fragment. The p16-luc mice were then subjected to noninvasive 
bioluminescence imaging (BLI) under anesthesia as described 
previously (Ohtani et al., 2007). Although previous studies re-
ported that p16
Ink4a protein expression is virtually undetectable in 
the normal tissues of young humans and rodents (Zindy et al., 
1997; Nielsen et al., 1999), BLI was sufficiently sensitive to de-
tect p16-luc expression in the cervix, chest, central abdomen, and 
testis of 6-wk-old mice (Fig. 1 D, left). To define the organs ex-
pressing a high level of bioluminescence signal, the same mice 
were again subjected to BLI after incision through the mouth and 
anus under anesthesia (Fig. 1 D, right). As expected from non-
invasive BLI data (Fig. 1 D, left), significant levels of biolumines-
cence signals were observed in cervical lymph nodes (LNs), lung, 
mesenteric LNs, and testis (Fig. 1, D [right] and E). Notably, 
these levels were well correlated with not only exogenous (human) 
but also endogenous (mouse) p16
Ink4a mRNA expression (Fig. 1, 
E and F; and Fig. S1 D), indicating that the tissue-specific gene 
expression of the human p16
Ink4a gene is very similar to that of the 
mouse p16
Ink4a gene.
Induction of p16
Ink4a expression in cellular 
senescence and organismal aging
Because induction of p16
Ink4a expression is a hallmark of cellu-
lar senescence (Hara et al., 1996; Serrano et al., 1997), we next 
asked whether the human p16
Ink4a gene responds to senescence 
stimuli in murine cells. To this end, MEFs prepared from p16-luc 
mice were rendered senescent by either serial passage or ecto-
pic expression of oncogenic Ras in culture. Concurrent with the 
level of endogenous p16
Ink4a expression, luciferase activity was JCB • VOLUME 186 • NUMBER 3 • 2009   396
size for a further 18 wk (Fig. 4 A, bottom, early papilloma). 
Although bioluminescent signals were hardly detectable during 
this time, a significant level of bioluminescent signal was induced 
as papillomas stopped growing (Fig. 4 A, top, late papilloma). 
The levels of bioluminescent signals were well correlated with 
those of endogenous p16
Ink4a expression as well as other senes-
cence markers such as senescence-associated (SA) -galactosidase 
(-gal) activity (Dimri et al., 1995) and dephosphorylation of 
pRb (Fig. 4, A–C; Campisi, 2005), indicating that oncogenic 
Ras signaling derived from the endogenous H-ras gene indeed 
provokes p16
Ink4a expression accompanied by senescence cell 
cycle arrest in vivo.
Note that the level of p16
Ink4a expression in early papillo-
mas was slightly but consistently higher than those seen in nor-
mal skin (Fig. 4, B and C). However, because significant levels 
of pRb phosphorylation and Ki67 expression, which are mark-
ers for cell proliferation, were observed in early papillomas 
(Fig. 4 C), this level of p16
Ink4a expression does not appear to be 
high enough to induce senescence cell cycle arrest. Thus, it is 
tempting to speculate that p16
Ink4a may play a more important 
role or roles in late papillomas, presumably preventing malignant 
conversion of benign tumors. Indeed, by 30 wk after DMBA/TPA 
treatment, 33% of p16
Ink4a knockout mice (C57BL/6 back-
ground) had at least one carcinoma compared with 5% of the 
wild-type mice (unpublished data), indicating that p16
Ink4a plays 
an important role or roles in preventing malignant conversion of 
benign tumors. These results are somewhat consistent with a 
previous study showing that the tumor-free survival of DMBA-
treated  mice  was  substantially  reduced  in  p16
Ink4a  knockout 
mice (Sharpless et al., 2004).
The global level of histone 3 Lys9  
(H3K9) dimethylation (H3K9me2) is 
reduced in late papillomas
Given that oncogenic mutation in the H-ras gene is known to 
occur immediately after DMBA treatment (Quintanilla et al., 
1986) and was indeed observed in early papillomas (Fig. S3), it 
significantly increased upon induction of cellular senescence in 
both settings (Fig. 2), indicating that the human p16
Ink4a gene 
also responds to senescence stimuli in murine cells. Moreover, as 
the levels of mouse p16
Ink4a gene expression are increased in 
many different tissues with age (Zindy et al., 1997; Krishnamurthy 
et al., 2004), the levels of bioluminescent signals in p16-luc 
mice were dramatically increased during the aging process 
throughout the body (Fig. 3, A and B). However, the most strik-
ing increase was observed in the central abdomen and was found 
to be localized to the small intestine and spleen (Fig. 3, A and B; 
and Fig. S2). These levels were well correlated with both exoge-
nous (human) and endogenous (mouse) p16
Ink4a mRNA expres-
sion (Fig. 3, C and D). Collectively, these results indicate that 
overall regulation of human p16
Ink4a gene expression is very sim-
ilar to that of mouse p16
Ink4a gene expression, at least in mouse 
cells, illustrating the potential of p16-luc mice for analysis of 
p16
Ink4a gene expression against oncogenic stimuli in vivo.
Delayed response of p16
Ink4a expression 
against oncogenic Ras signaling in vivo
Although oncogenic Ras–induced senescence is widely ob-
served in cultured normal HDFs (Serrano et al., 1997; Serrano 
and Blasco, 2001; Campisi, 2005; Gil and Peters, 2006; Kim 
and Sharpless, 2006), freshly isolated HDFs are resistant to   
oncogenic Ras–induced senescence because of low level p16
Ink4a 
gene expression (Benanti and Galloway, 2004). To explore this 
notion in a more physiological setting rather than using ectopic 
expression of oncogenic Ras in cultured cells, the p16-luc mice 
were subjected to a conventional chemically induced skin papil-
loma protocol with a single dose of DMBA followed by multi-
ple treatments with TPA. Because this protocol causes an 
oncogenic mutation in the H-ras gene (Quintanilla et al., 1986), 
it appeared to be ideal for studying physiological responses of 
p16
Ink4a gene expression against oncogenic Ras signaling in liv-
ing animals. In agreement with previous studies (Quintanilla   
et al., 1986; Kemp, 2005), benign skin papillomas began to ap-
pear after 7 wk of treatment and continued to grow to a larger 
Figure 2.  Induction of human p16
Ink4a gene expression during the onset of cellular senescence in cultured MEFs. (A and B) Primary MEFs derived from the 
p16-luc mice were rendered senescent by either serial passage (A) or oncogenic Ras expression (retrovirus infection; B). The levels of endogenous p16
Ink4a 
expression and luciferase activity were measured. Representative data of three independent experiments are shown. As confirmation of senescence, rep-
resentative photographs of the cells stained for SA -gal activity are shown. -Actin was used as a loading control. The means ± SD of three independent 
experiments are shown. WB, Western blot.397 REAL-TIME IN VIVO IMAGING OF P16 EXPRESSION • Yamakoshi et al.
Figure 3.  The dynamics of p16
Ink4a gene expression during the aging process in vivo. (A) The same p16-luc mice were subjected to noninvasive BLI every 
2 wk throughout their entire life span. Representative images of 10 independent mice are shown. (B) The p16-luc mice (young and old) were subjected 
to noninvasive BLI. The same mice were then incised through mouth and anus under anesthesia. (A and B) The color bars indicate photons with minimum 
and maximum threshold values. (C) Bioluminescence intensity emitted from the organs from young (1.5 mo) and old (22.5 mo) mice were graphed (log10 
scale). The mean ± SD of five independent experiments is shown. (D) The levels of exogenous (human) p16
Ink4a gene expression and endogenous (mouse) 
p16
Ink4a gene expression from young (Y; 1.5 mo) and old (O; 22.5 mo) mice were analyzed by semiquantitative RT-PCR. -Actin was used as a loading 
control. Representative data of five independent experiments are shown.JCB • VOLUME 186 • NUMBER 3 • 2009   398
Figure 4.  The dynamics of p16
Ink4a gene expression during skin papilloma formation. (A) The p16-luc mice treated with DMBA/TPA were subjected to 
noninvasive BLI at the indicated time points after initiation of TPA treatment. Representative images of 10 independent experiments are shown (top). These 
papillomas were photographed in dimmed light (bottom). The color bar indicates photons with minimum and maximum threshold values. (B) Representative 
Western blots of biopsy samples of skin papillomas or control normal skin are shown using the antibodies indicated on the left. Vinculin was used as a load-
ing control. (C) Hematoxylin and eosin (HE) staining, SA -gal staining, and immunohistochemistry for endogenous p16
Ink4a expression, phosphorylation 
of pRb at Ser807, Ki67 expression, phosphorylation of histone H2AX (-H2AX), and phosphorylation of p53 at Ser18 were performed by using biopsy 
samples of skin papillomas or control normal skin. The boxes denote regions shown below at higher magnification (p16 staining). (D) The levels of ROS 
were measured by using biopsy samples of skin papillomas or control normal skin. The means ± SD of three independent experiments are shown.399 REAL-TIME IN VIVO IMAGING OF P16 EXPRESSION • Yamakoshi et al.
was puzzling that p16
Ink4a gene expression was fully induced in late 
but not early papillomas (Fig. 4, A–C). We first reasoned that the 
long latency period of p16
Ink4a gene expression may be caused by a 
spontaneous up-regulation of the intensity of Ras signaling because 
high levels but not low levels of oncogenic Ras expression have 
been shown to induce p16
Ink4a gene expression in transgenic mice 
carrying a tetracycline-inducible ras oncogene (Sarkisian et al., 
2007). However, unexpectedly, the levels of phosphorylated MEK 
(MAPK/ERK kinase), which is an indicator of Ras signaling, in 
early papillomas were even higher than those seen in late papillo-
mas (Fig. 4 B), implying that the effect or effects of oncogenic Ras 
signaling on the p16
Ink4a promoter (Serrano et al., 1997; Ohtani   
et al., 2001) may be counteracted in early papillomas.
To substantiate this idea, we next sought negative regula-
tors of p16
Ink4a expression whose activities are increased in early 
papillomas. In the course of our study, we found that the levels 
of DNMT1, which is known to repress p16
Ink4a expression (Robert 
et al., 2003), were significantly increased in early papillomas 
and were subsequently reduced in late papillomas (Fig. 4 B). 
These results led us to hypothesize that increased levels of 
DNMT1 may counteract the effects of oncogenic Ras signaling 
on the p16
Ink4a promoter in early papillomas and that the subse-
quent reduction of DNMT1 levels thereby allows derepression 
of p16
Ink4a gene promoter, presumably through altering the DNA 
methylation status of the p16
Ink4a gene promoter in late papillo-
mas. However, unexpectedly, the status of the CpG methylation 
around the p16
Ink4a promoter was not substantially different be-
tween early and late papillomas (Fig. 5), indicating that DNMT1 
may regulate p16
Ink4a gene expression either indirectly or through   
a different activity of DNMT1 in this setting.
It has recently been shown that DNMT1 also possesses an 
activity to enhance H3K9 methylation through interacting with 
G9a, a major H3K9 mono- and dimethyltransferase (Estève   
et al., 2006). Thus, we next examined the levels of H3K9 methyl-
ation during skin papilloma development. Interestingly, global 
levels of H3K9me2 were remarkably increased in early papillo-
mas and were reduced in late papillomas, which is consistent 
with the levels of DNMT1 during skin papilloma development 
(Fig. 4 B). These results, in conjunction with previous studies 
showing that the silencing of p16
Ink4a gene expression was asso-
ciated with H3K9 methylation in several human cancer cell 
lines (Nguyen et al., 2002; Bachman et al., 2003), led us to the 
hypothesis that the levels of DNMT1 may regulate p16
Ink4a ex-
pression, at least partly, through altering the levels of H3K9me2 
around the p16
Ink4a gene promoter region during DMBA/TPA-
induced skin papilloma development.
The balance between the intensity of 
Ras signaling and the levels of DNMT1 
expression regulates p16
Ink4a expression
To test this hypothesis and to delineate the molecular mecha-
nisms involved, we next used primary HDFs because mice lack-
ing the DNMT1 gene are embryonic lethal (Li et al., 1992) and 
the p16
Ink4a gene is exquisitely sensitive to tissue culture stress in 
mouse primary cells (Zindy et al., 1997; Parrinello et al., 2003). 
Of note, the levels of DNMT1 were initially increased by onco-
genic Ras expression and were subsequently reduced as cells 
reached to the senescence stage in cultured HDFs (Fig. 6 A). This 
is reminiscent of our results in DMBA/TPA-induced skin papil-
lomas (Fig. 4 B). Note that the levels of DNMT1 bound to the 
Figure  5.  Bisulfite  sequence  analysis  of  the  mouse 
p16
Ink4a  gene  promoter.  A  schematic  illustration  of  the 
mouse p16
Ink4a gene promoter is shown at the top, with 
the sequence numbered backwards from immediately be-
fore the initiating Met codon (the positions of the numbers 
are indicated by vertical dashes). The transcriptional start 
site is indicated by a thick vertical line, with the direc-
tion of transcription shown by the associated arrow. The 
coding region of the mouse p16
Ink4a gene is annotated 
and indicated with a closed box. The clustering of CpG 
dinucleotides is shown with thin vertical lines through the 
promoter region. The positions of the primers for methyl-
specific PCR are indicated below with two small arrows. 
Bisulfite-treated DNA was prepared from normal skin or 
early or late papillomas (Fig. 4). Methylation-specific PCR 
products were subcloned into the pGEM-T vector, and 10 
clones for each sample were sequenced. Representative 
results of three different experiments are shown.JCB • VOLUME 186 • NUMBER 3 • 2009   400
the  levels  of  DNMT1  bound  to  the  p16
Ink4a  gene  promoter   
and H3K9me2 around the p16
Ink4a gene promoter were also sub-
stantially reduced in DNMT1 knockdown cells (Fig. 6 D and 
Fig. S4 D). Therefore, it is likely that the level of the p16
Ink4a 
gene is regulated, at least partly, through the balance between 
the intensity of Ras signaling (positive factor) and the levels of 
DNMT1 expression (negative factor). Note that the intensity of 
the Ras signaling was very low in normal skin (Fig. 4 B). This 
may explain why the level of p16
Ink4a expression is very low de-
spite the low level of DNMT1 expression in normal skin (Fig. 4 B). 
Together, these results indicate that the increased level of DNMT1 
is likely to counteract the effects of oncogenic Ras signaling on 
the  p16
Ink4a  gene  promoter,  presumably  through  facilitating 
H3K9me2 around the p16
Ink4a gene promoter in early papillomas. 
p16
Ink4a gene promoter were significantly reduced in oncogenic 
Ras–induced senescence in cultured HDFs (Fig. S4 A). More-
over, the levels of H3K9me2 around the p16
Ink4a gene promoter 
were also substantially reduced in the same setting (Fig. 6 B), 
suggesting that a similar mechanism is likely to be involved in 
the regulation of p16
Ink4a gene expression by oncogenic Ras sig-
naling both in vitro (cultured HDFs) and in vivo (mouse skin).
It is noteworthy that substantial levels of both phosphory-
lated MEK, an indicator of Ras signaling (positive factor), and 
DNMT1 (negative factor) were observed in proliferating early 
passage HDFs (Fig. 6 A), and depletion of DNMT1 level by 
RNAi caused a substantial increase of p16
Ink4a gene expression 
accompanied by a senescence-like cell cycle arrest in early   
passage HDFs (Fig. 6 C and Fig. S4, B and C). Moreover,   
Figure 6.  Correlation between DNMT1 level and H3K9me2 level around the p16
Ink4a gene promoter. (A) Early passage TIG-3 cells were infected with 
retrovirus encoding oncogenic Ras (+H-RasV12). Cells were then subjected to Western blot (WB) analysis at the indicated times with the antibodies shown 
on the left and to analysis of intracellular levels of ROS. (B) Early passage TIG-3 cells were infected with retrovirus encoding oncogenic Ras (RasV12) or 
control empty vector for 10 d and were subjected to Western blotting with the antibodies shown, analysis of intracellular levels of ROS, and to ChIP analysis 
using the antibodies indicated (IP). The precipitated DNA was amplified by real-time quantitative PCR (qPCR) using primers specific for the p16
Ink4a gene 
promoter described previously (Bracken et al., 2007). (C and D) Early passage TIG-3 cells were infected with retrovirus encoding shRNA against DNMT1 
or control scramble shRNA. Cell extracts were prepared from cells at 7 d after selection with puromycin and were subjected to Western blotting and 
quantitative real-time RT-PCR (RT-qPCR) analysis for p16
Ink4a gene expression (C) and subjected to ChIP analysis using antibodies against H3K9me2 (D).   
(D) The precipitated DNA was amplified by real-time quantitative PCR using primers specific for the p16
Ink4a gene promoter described previously (Bracken 
et al., 2007). (A–D) The means ± SD of three independent experiments are shown.401 REAL-TIME IN VIVO IMAGING OF P16 EXPRESSION • Yamakoshi et al.
2008), we wondered whether p53 might have some influence 
over the DDR pathway activating p16
Ink4a gene expression in 
vivo. Indeed, phosphorylation of p53 at Ser18, which is a marker 
of p53 activation, was observed in early papillomas (Fig. 4 C), 
implying  that  p53  may  prevent  accumulation  of  DDR  and 
thereby counteract p16
Ink4a gene expression in vivo. To explore 
this idea, we again took advantage of using p16-luc mice. The 
p16-luc mice were crossed into a p53 homozygous-null genetic 
background, and p16-luc mice lacking the p53 gene were sub-
ject to noninvasive BLI at the indicated times after treatment 
with DXR. Intriguingly, although bioluminescent signals were 
only slightly induced after treatment with DXR in p16-luc mice, 
this effect was dramatically enhanced by p53 deletion, espe-
cially in highly proliferative tissues such as thymus or small in-
testine  (Fig.  7 A).  Note  that  the  levels  of  bioluminescence 
signals were well correlated with those of endogenous p16
Ink4a 
gene expression as well as the number of DNA damage foci in 
p16-luc mice (Fig. 7, B and C). Moreover, RNAi-mediated de-
pletion of p53 also increased the levels of p16
Ink4a expression in 
cultured HDFs (Fig. 7 D), precluding the possibility that the en-
hanced expression of the p16
Ink4a gene in p53 knockout mice 
was an artifact of BLI and/or the generation of p53 knockout 
mice. Therefore, these results indicate that loss of p53 function 
indeed accelerates the DDR pathway activating p16
Ink4a gene 
expression, unveiling a regulatory circuit between the p53 and 
p16
Ink4a tumor suppressors.
To further verify the biological significance of the regula-
tory circuit between p53 and p16
Ink4a, we next asked whether 
p16
Ink4a gene expression is induced naturally in the setting of 
p53 deletion. Interestingly, a substantial increase of biolumines-
cence signals over controls was indeed observed in the thymus 
of nearly all mice lacking p53 around 10–20 wk after birth   
(Fig. 8 A). Note that p53 knockout mice are shown to be highly 
susceptible  to  thymic  lymphoma  (Donehower  et  al.,  1992). 
Therefore, it is very likely that deletion of the p53 gene causes 
a strong oncogenic stimulus that provokes p16
Ink4a expression in 
the thymus. Indeed, the levels of bioluminescent signals were 
well correlated with those of endogenous p16
Ink4a expression as 
well as -H2AX foci, ROS, and SA -gal activity in thymic tis-
sues of p53 knockout mice (Fig. 8, B–E). Moreover, a substan-
tial reduction of DNMT1 gene expression was also observed in 
thymic tissues of p53 knockout mice (Fig. 8 F). Altogether, al-
though additional mechanisms may be at play here, these data 
strongly suggest that inactivation of p53 potentiates the DDR 
pathway activating p16
Ink4a gene expression and thereby causing 
senescent cell cycle arrest in highly proliferating tissues such as 
thymus. However, because p53 knockout mice are highly sus-
ceptible to thymic lymphoma (Donehower et al., 1992), induc-
tion of p16
Ink4a appears to be insufficient for long-term stability 
of senescence cell cycle arrest in the absence of p53, which is 
the guardian of the genome.
Discussion
The regulation of human p16
Ink4a gene expression has re-
mained incompletely defined, at least in part, because p16
Ink4a 
gene expression is rapidly induced by tissue culture stress in   
It is also interesting to note that oncogenic Ras signaling is 
shown to activate the DNMT1 gene promoter (MacLeod et al., 
1995). Thus, the induction of DNMT1 expression appears to be 
caused by a direct effect of oncogenic Ras expression. However, 
it remains unclear why DNMT1 levels are subsequently reduced 
in late papillomas and in oncogenic Ras–induced senescence in 
cultured HDFs (Figs. 4 B and 6 A).
DDR provokes p16
Ink4a expression through 
reduction of DNMT1 levels
Because several lines of evidence suggest that DDRs triggered 
by hyper–cell proliferation play a key role or roles in the onset 
of oncogene-induced senescence (Bartkova et al., 2006; Di Micco 
et al., 2006; Mallette et al., 2007), we next asked whether   
DDR triggered by hyper–cell proliferation might be involved in 
the reduction of DNMT1 level in late papillomas. Indeed, a sig-
nificant increase of phosphorylation of pRb and expression of 
Ki67, which are markers for hyper–cell proliferation, were ob-
served before detection of -H2AX foci and phosphorylation of 
proteins containing the ATM (ataxia telangiectasia mutated)/
ATR (ATM and Rad3 related) substrate motif, which are signs 
of DDR, in skin papillomas (Fig. 4 C and Fig. S4 E). Moreover, 
treatment with doxorubicin (DXR), a DNA-damaging agent, 
caused significant reductions of DNMT1 and the H3K9me2 
modification around the p16
Ink4a gene promoter, accompanied 
by  induction  of  p16
Ink4a  gene  expression  in  cultured  HDFs   
(Fig. S5, A and B). Together, these results suggest that the accumu-
lation of DNA damage triggered by hyper–cell proliferation is 
likely to cause a reduction of DNMT1 levels in late papillomas.
To understand how DNA damage causes a reduction of 
DNMT1 levels, we next focused on the intracellular levels of 
reactive oxygen species (ROS) because ROS levels are known 
to be increased by both oncogenic Ras expression and DNA 
damage  (Fig.  S5  A;  Finkel  and  Holbrook,  2000;  Macleod, 
2008), and increased levels of ROS are shown to be essential for 
the  onset  of  oncogenic  Ras–induced  senescence  in  cultured 
HDFs (Lee et al., 1999). The levels of ROS were substantially 
increased  in  late  papillomas  and  in  oncogenic  Ras–induced   
senescence in cultured HDFs (Figs. 4 D and 6 A). Moreover,   
reduction of DNMT1 levels by oncogenic Ras expression was 
somewhat diminished when ROS production was attenuated by 
the addition of catalase in cultured HDFs (Fig. S5 C). Conversely, 
treatment with H2O2 to increase intracellular levels of ROS sig-
nificantly  reduced  the  levels  of  DNMT1  gene  expression  in 
HDFs (Fig. S5 D), presumably through blocking the activity of 
E2F transcription factor because E2F activity is known to acti-
vate DNMT1 gene expression (McCabe et al., 2005) and is re-
duced by treatment with H2O2 (not depicted). Together, these 
results provide compelling evidence that DNA damage provokes 
p16
Ink4a gene expression, at least partly, through blocking the lev-
els of DNMT1 gene expression by elevated levels of ROS.
Inactivation of p53 accelerates the DDR 
pathway activating p16
Ink4a gene expression
Because the p53 tumor suppressor is known to be activated im-
mediately after detection of DNA damage, preventing prolifera-
tion of damaged cells (Vousden and Lane, 2007; Riley et al., JCB • VOLUME 186 • NUMBER 3 • 2009   402
(2009) reported that one or two additional mouse Ink4a/Arf 
gene loci without a reporter gene caused an impairment of male 
germ cell production as well as reduced incidence of aging- 
associated cancer and extended longevity. However, because 
the p16-luc fusion protein does not function as a Cdk inhibitor 
(Fig. S1 A), it is most likely that these seemingly contradictory 
data are, at least partly, caused by the difference of p16
Ink4a ac-
tivity between our mice and the mice of Matheu et al. (2009). 
nontransformed cells (Shay and Wright, 2007). To circumvent 
this problem, we developed a new transgenic mouse model that 
carries the entire human p16
Ink4a gene locus tagged with lucifer-
ase. In this mouse model, luciferase activity allows expression 
of the human p16
Ink4a gene to be monitored under various physi-
ological  conditions  in  living  mice. We  did  not  observe  any 
phenotypic differences between p16-luc mice and control non-
transgenic  mice  (unpublished  data),  although  Matheu  et  al. 
Figure 7.  Accelerated induction of p16
Ink4a gene expression by DNA damage in mice lacking p53. (A) 8-wk-old p16-luc mice lacking the p53 gene (p53
/) 
or their wild-type controls (p53
+/+) were injected i.p. with 20 µg/g DXR and subjected to noninvasive BLI at the indicated time points. The same mice were then 
sacrificed, tissues were rapidly removed and placed in culture dishes, and ex vivo tissue BLI was performed. The tissues examined were as follows: 1, brain; 
2, cervical LNs; 3, heart; 4, lung; 5, thymus; 6, small intestine; 7, liver; 8, kidney; 9, spleen. The color bars indicate photons with minimum and maximum 
threshold values. Representative images of five different experiments are shown. Schematic drawings illustrating the mouse bodies are shown (dotted lines). 
(B and C) Isolated tissues were subjected to analysis of quantitative real-time RT-PCR (RT-qPCR) for p16
Ink4a gene expression (B) or to immunofluorescence analy-
sis using antibody against -H2AX (red; C). DNA was stained with DAPI (blue). The histogram indicates the percentage of nuclei that were positive for -H2AX 
staining. The means ± SD of three independent experiments are shown. (C) Enlarged images of the boxed areas are shown below. Small intestinal crypts are 
marked by dashed lines. (D) Early passage TIG-3 cells were infected with retrovirus encoding shRNA against p53 or control scramble shRNA. Cell extracts were 
prepared after selection with puromycin and subjected to Western blotting using the antibodies shown on the left. -Actin was used as a loading control.403 REAL-TIME IN VIVO IMAGING OF P16 EXPRESSION • Yamakoshi et al.
tool for studying physiological response of p16
Ink4a gene expres-
sion against oncogenic stress in vivo.
By monitoring and quantifying p16
Ink4a gene expression 
repeatedly in the same mouse throughout DMBA/TPA-induced 
Interestingly, the human p16
Ink4a gene and mouse p16
Ink4a gene 
are regulated similarly in mouse cells, as judged by several 
well-accepted criteria (Figs. 1–4). Collectively, these results in-
dicate that the p16-luc transgenic mouse line could be an ideal 
Figure 8.  Induction of p16
Ink4a gene expression in p53 knockout mice. (A) p16-luc mice lacking the p53 gene (p53
/) or their wild-type controls (p53
+/+) 
were subjected to noninvasive BLI at the indicated age. The same mice were then incised under anesthesia (photographed under regular light) and sub-
jected to BLI again (invasive BLI). Representative images of five different experiments are shown. The color bars indicate photons with minimum and maxi-
mum threshold values. Schematic drawings illustrating the mouse bodies are shown (dotted lines). The arrows show bioluminescence signals derived from 
thymus. (B–F) Thymus tissue was isolated from both genotypes of 10-wk-old mice (A) and subjected to analysis of quantitative real-time RT-PCR (RT-qPCR) 
for p16
Ink4a gene expression (B) or DNMT1 gene expression (F) or histochemistry (hematoxylin and eosin [H&E] staining and SA -gal staining; E), -H2AX 
foci (C), or intracellular levels of ROS (D). The means ± SD of three independent experiments are shown.JCB • VOLUME 186 • NUMBER 3 • 2009   404
promoters in senescent HDFs. Collectively, with our observations 
at the p16
Ink4a gene promoter, it appears that widespread redistribu-
tion of H3K9 methylation may occur during senescence onset.
Therefore, we propose a model in which although onco-
genic Ras signaling has a potential to activate p16
Ink4a gene ex-
pression (Serrano et al., 1997; Serrano and Blasco, 2001; Ohtani 
et al., 2001), this effect is initially counteracted by the elevation 
of DNMT1 levels and thereby causes hyper–cell proliferation. 
However, because hyper–cell proliferation tends to cause DNA 
damage and elevation of ROS, DNMT1 gene expression is even-
tually reduced by this ROS, leading to epigenetic derepression 
of p16
Ink4a gene expression and thus senescence cell cycle arrest 
(Fig. 9). Importantly, moreover, this pathway is more potenti-
ated in the setting of p53 deletion because p53 tends to prevent 
proliferation of damaged cells that cause further accumulation 
of DNA damage (Fig. 9; Vousden and Lane, 2007; Riley et al., 
2008). Indeed, the DDR pathway activating p16
Ink4a gene ex-
pression was provoked in the thymus of nearly all of the mice 
lacking p53 around 10–20 wk after birth (Fig. 8). Therefore, it 
is possible that p16
Ink4a may play a backup tumor suppressor 
role in case p53 is accidentally inactivated, especially in highly 
proliferative tissue such as thymus. Indeed, it has previously 
been shown that overexpression of Aurora A resulted in a sig-
nificant induction of p16
Ink4a expression in the mammary glands 
of p53 knockout mice (Zhang et al., 2008). Together, our find-
ing may help to explain why mice doubly deficient for p53 and 
p16
Ink4a showed an increased rate of tumor formation (Sharpless 
skin  papilloma  development,  we  unveiled  the  dynamics  of 
p16
Ink4a  gene  expression  against  oncogenic  Ras  signaling  in 
vivo (Fig. 4 A). Curiously, although the intensity of Ras signal-
ing in early papillomas is higher than that in late papillomas 
(Fig. 4 B), a significant induction of p16
Ink4a expression was ob-
served in late but not in early papillomas (Fig. 4, A–C), suggest-
ing that the effect or effects of oncogenic Ras signaling on the 
p16
Ink4a gene promoter (Serrano et al., 1997; Ohtani et al., 2001) 
may be counteracted by negative regulators of p16
Ink4a gene ex-
pression in early papillomas. Interestingly, the levels of DNMT1, 
which is a negative regulator of p16
Ink4a gene expression (Robert 
et al., 2003), were substantially increased in early papillomas 
and were subsequently reduced in late papillomas (Fig. 4 B). 
Moreover, similar kinetics of DNMT1 expression were also ob-
served in the setting of oncogenic Ras–induced senescence in 
cultured HDFs (Fig. 6 A), and depletion of DNMT1 by RNAi 
caused an increase of p16
Ink4a gene expression in proliferating 
HDFs (Fig. 6 C). Thus, it is most likely that increased levels of 
DNMT1 expression counterbalance the levels of p16
Ink4a gene 
expression in early papillomas, with the subsequent reduction 
of DNMT1 levels resulting in the induction of p16
Ink4a expres-
sion in late papillomas.
Because Ras signaling is known to activate the DNMT1 
gene promoter (MacLeod et al., 1995), it is most likely that the 
induction of DNMT1 in early papillomas is a direct effect of   
oncogenic Ras signaling (Fig. 4 B). However, it was unclear how 
DNMT1 is reduced in late papillomas (Fig. 4 B). Our results 
strongly suggest that DDR triggered by hyper–cell proliferation 
plays a critical role or roles in blocking the level of DNMT1 gene 
expression, at least partly, through the elevation of ROS level 
(Figs. 4 D and 6 A and Fig. S5). Note that DNMT1 gene expres-
sion is regulated by E2F (McCabe et al., 2005) and that E2F ac-
tivity is reduced by H2O2 treatment (unpublished data). Therefore, 
it is possible that ROS regulates DNMT1 expression, at least in 
part, through E2F. These results, together with the observation 
that depletion of DNMT1 causes up-regulation of p16
Ink4a gene 
expression in cultured HDFs (Fig. 6 C), indicate that DDR plays 
a key role in the induction of p16
Ink4a gene expression through 
blocking the levels of DNMT1 expression in the setting of Ras-
induced senescence both in vitro and in vivo.
Despite significant differences in the levels of DNMT1 
expression, we were unable to see substantial differences in the 
status of the CpG methylation around the p16
Ink4a gene promoter 
between early and late papillomas (Fig. 5). However, interest-
ingly, global levels of H3K9me2 were strikingly increased in 
early papillomas and were reduced in late papillomas, which is 
consistent with the changing levels of DNMT1 in these settings 
(Fig. 4 B). Moreover, local levels of H3K9me2 around the p16
Ink4a 
promoter were also reduced in oncogenic Ras–induced senes-
cence and in DNMT1 depletion in cultured HDFs (Fig. 6, B and D). 
These results, together with a recent observation that DNMT1 
possesses an activity to enhance H3K9me2 through interacting 
with G9a (Estève et al., 2006), suggest that DNMT1 regulates 
p16
Ink4a gene expression through altering the H3K9me2 status 
around the p16
Ink4a gene promoter during oncogenic Ras–induced 
senescence. It is noteworthy that Narita et al. (2003) have reported 
an increase in H3K9 methylation specifically at E2F target   
Figure 9.  Cross talk between the p53 and p16 pathways through DDR. 
Although oncogenic Ras signaling has a potential to activate p16
Ink4a gene 
expression, this effect is initially counteracted by an elevation of DNMT1 
level and thereby causes a strong proliferative burst, resulting in the ac-
cumulation of DNA damage. The accumulation of DNA damage activates 
ROS production, which in turn blocks DNMT1 gene expression, thereby 
causing epigenetic derepression of p16
Ink4a gene expression and thus se-
nescence cell cycle arrest. This pathway is counterbalanced by the p53 
pathway because p53 is immediately activated by DNA damage and 
blocks proliferation of damaged cells that cause further accumulation of 
DNA damage. Thus, the DDR pathway activating p16
Ink4a expression is 
accelerated in the event of p53 inactivation.405 REAL-TIME IN VIVO IMAGING OF P16 EXPRESSION • Yamakoshi et al.
Blend  Taq  polymerase  (TOYOBO)  with  primers  specific  for  the  mouse 
p16
Ink4a gene, human p16
Ink4a gene, and mouse -actin gene as shown   
below. Human p16
Ink4a, 5-ACCAGAGGCAGTAACCATGC-3 (forward) 
and 5-TGTCGTTCGCGGGCGCAACTG-3 (reverse); mouse p16
Ink4a,   
5-GAACTCTTTCGGTCGTACCC-3 (forward) and 5-TGGGCGTGCTTG-
AGCTGA-3  (reverse);  and  -actin,  5-GTATGGAATCCTGTGGCATC-3 
(forward) and 5-AAGCACTTGCGGTGCACGAT-3 (reverse).
Real-time RT-PCR
Quantitative real-time RT-PCR was performed using SYBER Premix EX Taq 
system (TAKARA) and a Prism 7900HT (ABI). Amplified signals were con-
firmed to be single bands by gel electrophoresis and were normalized to 
the levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Data 
were analyzed using SDS2.1 software (ABI). The PCR primer sequences   
used are as follows: GAPDH, 5-CAACTACATGGTTTACATGTTC-3 (for-
ward) and 5-GCCAGTGGACTCCACGAC-3 (reverse); human p16
Ink4a, 
5-CCCAACGCACCGAATAGTTA-3 (forward) and 5-ACCAGCGTGTCCA-
GGAAG-3  (reverse);  mouse  p16
Ink4a,  5-GAACTCTTTCGGTCGTACCC-3 
(forward)  and  5-CGAATCTGCACCGTAGTTGA-3  (reverse);  human 
DNMT1, 5-TACCTGGACGACCCTGACCTC-3 (forward) and 5-CGTTG-
GCATCAAAGATGGACA-3 (reverse); mouse DNMT1, 5-GAGGAAGGC-
TACCTGGCTAA-3  (forward)  and  5-AGTGAGAGTGTGTGTTCCGT-3 
(reverse); 5 end of the transgene, 5-GCAGAAAGCCAGGAGAGGTG-3 
(forward) and 5-GCCGCATGGACACAGGTGAC-3 (reverse); 3 end of 
the transgene, 5-TCCCTTATCCTTACCCCACT-3 (forward) and 5-TGAT-
GATGATCCTATGGTGT-3 (reverse); and GAPDH (human/mouse common 
sequence), 5-AGACCACAGTCCATGCCATC-3 (forward) and 5-TTGC-
CCACAGCCTTGGCAG-3 (reverse).
Histology and immunohistochemistry
Immunohistochemistry was performed as previously described (Ohtani 
et al., 2007). The primary antibodies used were mouse p16 (Santa Cruz 
Biotechnology, Inc.), -H2AX (Millipore), phospho-pRb (Ser807/811; Cell 
Signaling Technology), Ki67 (RTU-Ki67-MM1; Novocastra), and phospho 
(Ser/Thr)-ATM/ATR  substrate  (Cell  Signaling  Technology).  The  fluoro-
chromes  used  were  DAPI  (Dojindo)  and  Alexa  Fluor  546  (Invitrogen). 
Microscopic images were obtained at RT by using a fluorescence micro-
scope (AxioImager.A1; Carl Zeiss, Inc.) connected with a CCD camera 
(AxioCamMRc5; Carl Zeiss, Inc.) through an EC Plan-Neofluar 10× NA 
0.3 Ph1, 40× NA 0.75 Ph2, or 63× NA 1.25 oil Ph3 objective using 
AxioVision software (Carl Zeiss, Inc.).
Cells and cell culture experiments
Early passage (45 PDLs) HDFs (TIG-3 cells), MEFs, 293T cells, and U20S 
cells were cultured in DME supplemented with 10% FBS at 37°C. Retroviral 
infection was performed as previously described (Takahashi et al., 2006). 
For RNAi experiments, HDFs were infected with retrovirus encoding short 
hairpin RNA (shRNA) as described previously (Maehara et al., 2005). 
RNAi sequences used were as follows: scramble, 5-CATTGCTATAGAG-
GCAGAT-3; human DNMT1, 5-TGGTCCGCATGGGCTATCAGT-3; and 
human p53, 5-GACTCCAGTGGTAATCTAC-3.
SA -gal staining was performed as described previously (Dimri 
et al., 1995). Microscopic images were obtained at RT by using an in-
verted microscope (AxioVert 135; Carl Zeiss, Inc.) connected with an   
AxioCamMRc5 CCD camera through an Achrostigmat 10× NA 0.25 Ph1 
objective using AxioVision software. SA heterochromatic foci analysis 
was performed using DAPI as described previously (Narita et al., 2003). 
Microscopic images were obtained at RT by using an AxioImager.A1 
fluorescence microscope connected with an AxioCamMRc5 CCD camera 
through an EC Plan-Neofluar 63× NA 1.25 oil Ph3 objective using Axio-
Vision software.
Western blot analysis
Immunoblotting was performed as previously described (Takahashi et al., 
2006). Primary antibodies used were human p16 (EMD), Ras (EMD), pRb 
(BD), vinculin (hVIN-1; Sigma-Aldrich), mouse p16 (Santa Cruz Biotechnol-
ogy, Inc.), DNMT1 (Santa Cruz Biotechnology, Inc.), H3K9me2 (Abcam), 
phospho-MEK1/2  (Ser217/221;  Cell  Signaling  Technology),  MEK1/2 
(Cell Signaling Technology), -actin (AC-74; Sigma-Aldrich), and phospho-
p53 (Cell Signaling Technology).
Bisulfite sequencing analysis
Bisulfite sequencing analysis was performed as described previously   
(Suzuki et al., 2006).
et al., 2002; Terzian et al., 2008) and why the combination of 
p53 and p16
Ink4a loss frequently occurred in human cancer cells 
(Malumbres and Barbacid, 2001).
However, it is clear that all aspects of p16
Ink4a regulation 
cannot be explained by factors described in this study and that the 
p16
Ink4a gene is subject to multiple levels of control (Jacobs et al., 
1999; Passegué and Wagner, 2000; Ohtani et al., 2001, 2003; 
Gonzalez et al., 2006; Bracken et al., 2007; Kotake et al., 2007; 
Baker et al., 2008; Kia et al., 2008; Agger et al., 2009; Barradas 
et al., 2009; Tzatsos et al., 2009; Witcher and Emerson, 2009). 
Nonetheless, our results uncover an unexpected link between p53 
and p16
Ink4a gene expression, expanding our understanding of how 
p16
Ink4a gene expression is induced by oncogenic stimuli in vivo 
and open up new possibilities for its control.
Materials and methods
Generation of p16-luc mice
A large human genomic DNA segment (195.4 kb) containing the human 
p16
Ink4a gene was obtained from BACPAC Resources Center. The terminal 
sequences were determined with primers complementary to the insert-flanking 
elements of the bacterial artificial chromosome (BAC) vector (pBACe3.6). The 
cDNA fragment encoding firefly luciferase was inserted to the 3 end of the 
p16
Ink4a coding sequences using a Counter Selection BAC Modification kit 
(Gene Bridges). The DNA was digested with NotI and then used for micro-
injection. The transgenic mouse strain was generated by pronuclear micro-
injection of the reporter transgene into fertilized ICR oocytes. One transgenic 
line, p16-luc (line number CDB0416T-53), was selected because transgene 
integrity was complete. For the generation of compound mice, p16-luc mice 
were crossed with C57BL/6 mice for eight generations and then crossed with 
p53 knockout mice (C57BL/6; Ohtani et al., 2007). p16
Ink4a knockout mice 
(C57BL/6) were provided by N.E. Sharpless (University of North Carolina 
Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sharpless et al., 
2004). All animals were cared for by using protocols approved by the 
Committee for the Use and Care of Experimental Animals of the Japanese 
Foundation for Cancer Research and/or the University of Tokushima.
BLI and image acquisition
For the detection of luciferase expression, mice were anesthetized and 
injected i.p. with 75 mg/kg d-luciferin sodium salt 5 min before beginning 
photon recording. Photons emitted from living mice or from isolated organs 
were acquired as described previously (Ohtani et al., 2007). In brief, mice 
were placed in the light-tight chamber, and a grayscale image of the mice 
was first recorded with dimmed light followed by acquisition of the lumines-
cence image using a cooled charge-coupled device (CCD) camera (PIXIS 
1024B; Princeton Instruments). The signal to noise ratio was increased by 
2 × 2 binning and 15-min exposure. For colocalization of the luminescent 
photon emission on the animal body, grayscale and pseudocolor images 
were merged by using Image-Pro Plus (Media Cybernetics).
Tumor induction experiments
10 mice of the p16-luc line in the resting phase of the hair cycle (8 wk old) 
were shaved and treated with 100 µg DMBA (7,12-dimethylbenz[a]anthra
cene) in 100 µl acetone. 1 wk after DMBA treatment, mice were subse-
quently treated twice a week with 12.5 µg TPA (12-o-tetradecanoylphorbol 
13-acetate) in 100 µl acetone for 15 wk. Control mice were treated with 
acetone instead of DMBA/TPA.
H-ras sequencing
Total RNA was isolated from skin papilloma and control normal tissues using 
TRIZOL reagent (Invitrogen). RNA was converted to cDNA by using oligo 
(dT) primer, and a 330-bp PCR fragment containing exon 2 of the H-ras gene 
was amplified with the 5-TGGGGCAGGAGCTCCTGGAT-3 and 5-CTG-
TACTGATGGATGTCCTC-3 primers. PCR fragments were subcloned using 
pGEM-T Easy vector system (Promega) and were sequenced by using Dye-
Terminator and Big-Dye cycle sequencing systems (Applied Biosystems).
Semiquantitative RT-PCR
Total RNA was isolated using TRIZOL reagent, and 2 µg of total RNA was 
used for the reverse transcription reaction. The PCR was performed using JCB • VOLUME 186 • NUMBER 3 • 2009   406
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